CAL056 mesylate

CAL056 mesylate is a small molecule drug developed by Calgent Biotechnology for the treatment of immune system diseases, respiratory diseases, and skin and musculoskeletal diseases. It has been investigated primarily for osteoarthritis, pulmonary fibrosis, and rheumatoid arthritis. The drug has also been studied in patients with resistant or refractory solid tumors in a phase I clinical trial to evaluate its safety, tolerability, pharmacokinetics (PK), preliminary efficacy, and pharmacodynamics. Orphan drug designation was granted by the US FDA in 2019. The precise mechanism of action is not fully disclosed publicly; however, some sources suggest it may act as an ITCH inhibitor (E3 ubiquitin-protein ligase ITCH), which could modulate immune responses relevant to its indications[1][2][3][5].